Nā huahana

ʻO nā lāʻau antineoplastic Fluorouracil he mau lāʻau lapaʻau o ka fluorouracil.Ke hana nei ka thymidine phosphorylase i loko o ka ʻiʻo tumo e hoʻololi iā ia i fluorochemicalbook uracil i loko o ka ʻōpū, a laila e hana ana i kahi hopena anti-tumor.He ikaika kona ʻano anti-tumor, a haʻahaʻa kona ʻona.Hoʻohana maʻi ʻia no ka maʻi maʻi ʻōpū, ka maʻi maʻi colorectal, ka maʻi maʻi umauma, hiki i ke kala kala ke piʻi ma mua o 30%.

ʻAʻole maopopo ka maikaʻi o ka chemotherapy systemic no ka hoʻolaha peritoneal o ka maʻi maʻi ʻōpū.Ua loiloi ʻia ka maikaʻi o ka paclitaxel i kēlā me kēia pule me ka doxifluridine (5'-DFUR) i nā maʻi maʻi maʻi ʻōpū me nā ascites malignant.ʻO ka mālama ʻana he paclitaxel intravenously (iv) i lawelawe ʻia ma 80 mg/m(2) i nā lā 1, 8 a me 15 i kēlā me kēia 4 pule, a me ka doxifluridine i hāʻawi waha ʻia ma 533 mg/m(2) i nā lā 1-5 i kēlā me kēia pule.Ua hoʻoholo ʻia ka pane pane no nā maʻi me ka ascites ma muli o ka Japanese Classification of Gastric Carcinoma.Eia kekahi, ua ana ʻia ka ʻike o ka paclitaxel i nā ascites. Ua noiʻi ʻia nā maʻi he iwakāluakūmāhā.ʻO ka helu pane (RR) he 41.7%, me ke kala piha (CR) a me ke kala ʻāpana (PR) i nā maʻi 4 a me 6, kēlā me kēia.Ua mālama ʻia ka neʻe ʻana o ka paclitaxel i nā ascites ma waena o 0.01 μM a me 0.05 μM a hiki i 72 mau hola.ʻO ka median holoʻokoʻa holoʻokoʻa (OS) he 215 mau lā, a he 29.2% ka helu ola makahiki hoʻokahi.ʻAʻole i ʻike ʻia kahi mea ʻawaʻawa.